.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Fuji
Queensland Health
Dow
Healthtrust
Colorcon
Boehringer Ingelheim
Argus Health
Cipla
AstraZeneca

Generated: December 16, 2017

DrugPatentWatch Database Preview

Vertex Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for VERTEX PHARMS, and what generic alternatives to VERTEX PHARMS drugs are available?

VERTEX PHARMS has four approved drugs.

There are twenty US patents protecting VERTEX PHARMS drugs.

There are three hundred and thirty-one patent family members on VERTEX PHARMS drugs in forty-one countries and thirty-three supplementary protection certificates in fourteen countries.

Summary for Vertex Pharms

International Patents:331
US Patents:20
Tradenames:3
Ingredients:3
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vertex PharmsKALYDECOivacaftorTABLET;ORAL203188-001Jan 31, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Vertex PharmsKALYDECOivacaftorTABLET;ORAL203188-001Jan 31, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
Vertex Pharms IncORKAMBIivacaftor; lumacaftorTABLET;ORAL206038-002Sep 28, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Vertex PharmsKALYDECOivacaftorTABLET;ORAL203188-001Jan 31, 2012RXYesYes► Subscribe► SubscribeYY► Subscribe
Vertex PharmsKALYDECOivacaftorTABLET;ORAL203188-001Jan 31, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Vertex PharmsKALYDECOivacaftorTABLET;ORAL203188-001Jan 31, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
Vertex Pharms IncORKAMBIivacaftor; lumacaftorTABLET;ORAL206038-001Jul 2, 2015RXYesYes► Subscribe► SubscribeYY► Subscribe
Vertex Pharms IncORKAMBIivacaftor; lumacaftorTABLET;ORAL206038-001Jul 2, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Vertex Pharms IncKALYDECOivacaftorGRANULE;ORAL207925-001Mar 17, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Vertex Pharms IncORKAMBIivacaftor; lumacaftorTABLET;ORAL206038-002Sep 28, 2016RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expirations for VERTEX PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe
► Subscribe ► Subscribe

Non-Orange Book Patents for Vertex Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,461,156Modulators of ATP-binding cassette transporters► Subscribe
8,829,204Modulators of ATP-binding cassette transporters► Subscribe
9,434,717Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-- methylpyridin-2-yl) benzoic acid► Subscribe
8,318,733Modulators of ATP-binding cassette transporters► Subscribe
9,139,530Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide► Subscribe
7,754,739Modulators of CFTR► Subscribe
2,014,187,770► Subscribe
9,090,619Modulators of ATP-binding cassette transporters► Subscribe
7,956,052Modulators of ATP-binding cassette transporters► Subscribe
8,252,923Peptidomimetic protease inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Vertex Pharms Drugs

Country Document Number Estimated Expiration
Australia2006332726► Subscribe
South Korea20100043293► Subscribe
South Korea101561482► Subscribe
Slovenia2774925► Subscribe
Austria483686► Subscribe
Denmark2404919► Subscribe
EcuadorSP034493► Subscribe
Israel154671► Subscribe
New Zealand587551► Subscribe
Australia2010251789► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Vertex Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90007-2Sweden► SubscribePRODUCT NAME: TELAPREVIR OCH FARMACEUTISKT GODTAGBARA SALTER OCH/ELLER SOLVAT AV TELAPREVIR ELLER SOLVAT AV SADANA SALTER; REG. NO/DATE: EU/1/11/720/001 20110919
C0018France► SubscribePRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
960Luxembourg► Subscribe91960, EXPIRES: 20260831
2012 00007Denmark► Subscribe
12/009Ireland► SubscribePRODUCT NAME: TELAPREVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT AND/OR SOLVATE THEREOF OR SOLVATES OF SUCH SALTS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
2012003Lithuania► SubscribePRODUCT NAME: TELAPREVIRUM; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
0160015 00195Estonia► SubscribePRODUCT NAME: LUMAKAFTOOR / IVAKAFTOOR;REG NO/DATE: EU/1/15/1059 24.11.2015
2015 00038Denmark► SubscribePRODUCT NAME: IVACAFTOR, N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLIN-3-CARBOXAMID ELLER ET FARMACEUTISK ACCEPTABLET SALT DERAF; REG. NO/DATE: EU/1/12/782/001-002 20120723
2015028,C1773816Lithuania► SubscribePRODUCT NAME: IVAKAFTORAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002, 0120723
1320540/01Switzerland► SubscribeFORMER OWNER: VERTEX PHARMACEUTICALS INCORPORATED, US
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
UBS
Healthtrust
AstraZeneca
US Army
QuintilesIMS
Federal Trade Commission
Cipla
Novartis
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot